Charity organisation Sickle Cell Society has described the recommendation as a “major breakthrough” for sickle cell patients.

With the addition of Casgevy, Children’s Hospital Los Angeles now offers two gene therapies for sickle cell, the first being Lyfgenia.

The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...

Pfizer slashed its production targets for its COVID-19 vaccine ... Vertex's gene-editing therapy for sickle cell disease, Casgevy, has been given the nod for use by the NHS in England after ...

Its first treatment, Casgevy, earned approval from the Food and Drug Administration (FDA) to treat sickle cell disease in December 2023. Last January, the FDA approved Casgevy again to treat ...

“Building on the success of CASGEVY’s launch, we continue to broaden our portfolio across oncology, autoimmune and cardiometabolic indications. 2025 promises to be a milestone-rich ...

However, instead of directly editing a faulty gene, Casgevy instead takes advantage of a process ... where they multiply and ...

Vertex offers up to $70,000 in fertility services assistance for patients undergoing Casgevy treatment. HHS claims Vertex’s program incentivizes patients to choose its gene therapy over competitors.